Save your place

Sign in to WhoBought

Please try again later.

Zentalis Pharmaceuticals, Inc. (ZNTL) institutional ownership

Latest close $4.45 Jul 23, 2026
Market cap$96M 52-week range SectorHealthcare
Funds holding · Q1 2026
91
reported ZNTL position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
53 buyers · 38 sellers

Zentalis Pharmaceuticals, Inc. (ZNTL) price and institutional activity

Dates

Q1 2026

$0 bought by 53 investors
Squadron Capital Management LLCTwo Sigma Investments, LP +51 more
$0 sold by 38 investors
Two Sigma Advisers, LPRenaissance Technologies LLC +36 more
Bought Sold Totals per quarter; hover a bar for the names.

Zentalis Pharmaceuticals, Inc. (ZNTL) institutional activity · 91

Investor Type Est. change Change Δ Own Date
Squadron Capital Management LLC · New
Change +3.6M Date Q1 2026
Squadron Capital Management LLC New· Q1 2026 +3.6M Q1 2026
Two Sigma Investments, LP · Added
Change +1.5M Δ Own +100.9% Date Q1 2026
Two Sigma Investments, LP Added· Q1 2026 +1.5M +100.9% Q1 2026
Two Sigma Advisers, LP · Exited
Change −1.5M Δ Own −100.0% Date Q1 2026
Two Sigma Advisers, LP Exited· Q1 2026 −1.5M −100.0% Q1 2026
Renaissance Technologies LLC Reduced· Q1 2026 −946K −32.8% Q1 2026
Qube Research & Technologies Ltd · Added
Change +620K Date Q1 2026
Qube Research & Technologies Ltd Added· Q1 2026 +620K Q1 2026
Millennium Management LLC · Added
Change +617K Date Q1 2026
Millennium Management LLC Added· Q1 2026 +617K Q1 2026
Susquehanna International Group, LLP · Added
Change +561K Date Q1 2026
Susquehanna International Group, LLP Added· Q1 2026 +561K Q1 2026
Gsa Capital Partners LLP · Reduced
Change −549K Date Q1 2026
Gsa Capital Partners LLP Reduced· Q1 2026 −549K Q1 2026
UBS Group AG · Reduced
Change −519K Date Q1 2026
UBS Group AG Reduced· Q1 2026 −519K Q1 2026
Morgan Stanley · Reduced
Change −453K Date Q1 2026
Morgan Stanley Reduced· Q1 2026 −453K Q1 2026
Goldman Sachs Group Inc · Added
Change +344K Date Q1 2026
Goldman Sachs Group Inc Added· Q1 2026 +344K Q1 2026
Cdc Financial, Inc. · New
Change +284K Date Q1 2026
Cdc Financial, Inc. New· Q1 2026 +284K Q1 2026
Woodline Partners LP · Reduced
Change −265K Date Q1 2026
Woodline Partners LP Reduced· Q1 2026 −265K Q1 2026
Xtx Topco Ltd · Reduced
Change −254K Date Q1 2026
Xtx Topco Ltd Reduced· Q1 2026 −254K Q1 2026
Bank of America Corp · Reduced
Change −235K Date Q1 2026
Bank of America Corp Reduced· Q1 2026 −235K Q1 2026
Data through Q1 2026 · filed Jun 4, 2026
15 of 91

Famous investor activity in Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Johnson David Michael · Director Grant (A) 57K
Owned 308K Trade date Jun 16, 2026 Filed date Jun 18, 2026
Johnson David Michael Director Grant (A) 57K 308K Jun 16, 2026 Jun 18, 2026
Skvarka Jan · Director Grant (A) 57K
Owned 264K Trade date Jun 16, 2026 Filed date Jun 18, 2026
Skvarka Jan Director Grant (A) 57K 264K Jun 16, 2026 Jun 18, 2026
Walker Luke Nathaniel · Director Grant (A) 57K
Owned 201K Trade date Jun 16, 2026 Filed date Jun 18, 2026
Walker Luke Nathaniel Director Grant (A) 57K 201K Jun 16, 2026 Jun 18, 2026
Kariuki Enoch · Director Grant (A) 57K
Owned 194K Trade date Jun 16, 2026 Filed date Jun 18, 2026
Kariuki Enoch Director Grant (A) 57K 194K Jun 16, 2026 Jun 18, 2026
Myers Scott Dunseth · Director Grant (A) 57K
Owned 396K Trade date Jun 16, 2026 Filed date Jun 18, 2026
Myers Scott Dunseth Director Grant (A) 57K 396K Jun 16, 2026 Jun 18, 2026
Campbell Shannon · Director Grant (A) 114K
Owned 114K Trade date May 26, 2026 Filed date May 27, 2026
Campbell Shannon Director Grant (A) 114K 114K May 26, 2026 May 27, 2026
Vultaggio Vincent · Officer Sell −$17K
Price $2.42 Qty −7K Owned 147K Trade date Feb 10, 2026 Filed date Feb 10, 2026
Vultaggio Vincent Officer Sell $2.42 −7K −$17K 147K Feb 10, 2026 Feb 10, 2026
Bruns Ingmar · Officer Sell −$802
Price $2.39 Qty −335 Owned 33K Trade date Feb 9, 2026 Filed date Feb 10, 2026
Bruns Ingmar Officer Sell $2.39 −335 −$802 33K Feb 9, 2026 Feb 10, 2026
Vultaggio Vincent · Officer Sell −$8K
Price $2.39 Qty −3K Owned 153K Trade date Feb 9, 2026 Filed date Feb 10, 2026
Vultaggio Vincent Officer Sell $2.39 −3K −$8K 153K Feb 9, 2026 Feb 10, 2026
Eastland Julia Marie · Director, Officer Sell −$2K
Price $2.39 Qty −889 Owned 79K Trade date Feb 9, 2026 Filed date Feb 10, 2026
Eastland Julia Marie Director, Officer Sell $2.39 −889 −$2K 79K Feb 9, 2026 Feb 10, 2026
Bruns Ingmar · Officer Sell −$7K
Price $2.43 Qty −3K Owned 34K Trade date Feb 6, 2026 Filed date Feb 10, 2026
Bruns Ingmar Officer Sell $2.43 −3K −$7K 34K Feb 6, 2026 Feb 10, 2026
Vultaggio Vincent · Officer Sell −$73K
Price $2.43 Qty −30K Owned 157K Trade date Feb 6, 2026 Filed date Feb 10, 2026
Vultaggio Vincent Officer Sell $2.43 −30K −$73K 157K Feb 6, 2026 Feb 10, 2026
Eastland Julia Marie · Director, Officer Sell −$19K
Price $2.43 Qty −8K Owned 80K Trade date Feb 6, 2026 Filed date Feb 10, 2026
Eastland Julia Marie Director, Officer Sell $2.43 −8K −$19K 80K Feb 6, 2026 Feb 10, 2026
Vultaggio Vincent · Officer Sell −$1K
Price $2.52 Qty −556 Owned 187K Trade date Feb 3, 2026 Filed date Feb 4, 2026
Vultaggio Vincent Officer Sell $2.52 −556 −$1K 187K Feb 3, 2026 Feb 4, 2026
Vultaggio Vincent · Officer Sell −$6K
Price $2.55 Qty −3K Owned 187K Trade date Feb 2, 2026 Filed date Feb 4, 2026
Vultaggio Vincent Officer Sell $2.55 −3K −$6K 187K Feb 2, 2026 Feb 4, 2026
15 of 22
15 of 22 Sign in to continue to older insider transactions.

Zentalis Pharmaceuticals, Inc. (ZNTL) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Matrix Capital Management Company, LP 14.0M
% of shares outstanding 19.8% Filing date Jun 20, 2023
Matrix Capital Management Company, LP 14.0M 19.8% Jun 20, 2023
Walters William T 13.5M
% of shares outstanding 19.7% Filing date Jan 5, 2026
Walters William T 13.5M 19.7% Jan 5, 2026
Walters William T 7.0M
% of shares outstanding 9.9% Filing date Jan 31, 2025
Walters William T 7.0M 9.9% Jan 31, 2025
FMR LLC 5.1M
% of shares outstanding 7.1% Filing date Oct 7, 2024
FMR LLC 5.1M 7.1% Oct 7, 2024
BlackRock Inc. 4.7M
% of shares outstanding 6.6% Filing date Jan 29, 2024
BlackRock Inc. 4.7M 6.6% Jan 29, 2024
Millennium Management LLC 3.8M
% of shares outstanding 5.3% Filing date Feb 4, 2025
Millennium Management LLC 3.8M 5.3% Feb 4, 2025
5am Opportunities II (gp), LLC 3.9M
% of shares outstanding 5.2% Filing date Dec 30, 2025
5am Opportunities II (gp), LLC 3.9M 5.2% Dec 30, 2025
Squadron Master Fund LP 3.7M
% of shares outstanding 5.1% Filing date Mar 3, 2026
Squadron Master Fund LP 3.7M 5.1% Mar 3, 2026
8 of 18

Zentalis Pharmaceuticals, Inc. (ZNTL) ownership FAQ

Who owns ZNTL?

91 reporting institutions disclosed ZNTL position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.